Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

Metabolic Syndrome Clinical Trial

— EAT 2  

Official title:

Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04583514
• Other study ID #: PBRC 2019-051
• Secondary ID: R01DK121944
• Status: Recruiting
• Phase: N/A
• Start date: September 15, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: December 2023
• Source: Pennington Biomedical Research Center
• Contact: Ursula White, Ph.D.
• Phone: 225-763-2656
• Email: ursula.white[@]pbrc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adipose, or fat, tissue is a plastic organ that retains the ability to expand and store excess calories during positive energy balance in humans. The capacity of subcutaneous (subQ) adipose tissue to expand and remodel is an important determinant of obesity-related health complications, and impaired expansion of subQ fat tissue is thought to contribute to the risk of diseases such as the Metabolic Syndrome (MetS) and type 2 diabetes mellitus (T2D). The objectives of the study are to evaluate the changes and mechanisms of (subQ) adipose tissue expandability that occur as a result of short-term weight gain and to investigate the effects on cardio-metabolic health outcomes. Findings from this study will provide new insight into the dynamics of adipose expansion and remodeling during changes in energy balance and how this may impact future fat tissue function and metabolic health.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 42 Years

Eligibility

Inclusion Criteria:

• Men and pre-menopausal women

• 18-42 years of age

• BMI 23-35 kg/m2 (± 0.5 will be accepted)

• Are willing to drink deuterium-labeled water (2H2O) for 8 weeks

• Are willing to be randomized to either a CTL or 30% OF group

• For women, if not using pharmaceutical (hormonal) contraception (i.e. birth control pills, vaginal ring, injections, or implant), must agree to use either a double barrier method as a form of birth control to prevent pregnancy (i.e. male condom with spermicide, with or without cervical cap or diaphragm); use implants or intrauterine contraceptive devices; have a tubal ligation (surgically sterile); practice abstinence; or be in an established relationship with a vasectomized or same sex partner during the entire duration of the study

• Must be willing to adhere to all study procedures, including attendance at all study visits

• If enrolled, agree to maintain the same level of physical activity throughout the duration of the study

• Must be willing to have blood stored for future research

Exclusion Criteria:

• Unstable weight in the last 3 months (± ~5% weight change)

• Diagnosis of Type 1 or 2 diabetes or a fasting blood glucose > 110 mg/dL

• Average screening blood pressure > 140/90 mmHg

• Diagnosis of major organ disease (e.g. heart, kidney, lung, thyroid, liver disease) or abnormal liver enzymes that are, in the opinion of the MI, clinically significant and represent a problem for study inclusion.

• Self-reported positive test for human immunodeficiency virus, hepatitis B or hepatitis C

• Any current or previous eating disorders

• Chronic use of systemic glucocorticoids (steroids), systemic adrenergic-stimulating agents, beta-blockers, antipsychotic medications, thiazolidinediones and other medications that may cause clinically significant weight gain or loss)

• Chronic use of prescription weight loss medications or over the counter weight loss medications which, in the opinion of the MI, will impact the study

• Chronic use of anti-depressant medications for less than 3 months

• Chronic smokers or users of tobacco products who cannot abstain for the duration of the inpatient visits

• Previous bariatric or other surgeries for obesity

• Had cancer in the last 5 years (some skin cancers acceptable)

• Pregnancy, breastfeeding, or planned pregnancy for the upcoming 6 months

• Partial or full hysterectomy

• PCOS

• Diagnosed psychotic conditions.

Related Conditions & MeSH terms

• Metabolic Syndrome
• Overweight
• Overweight and Obesity

Intervention

Behavioral:
• Control
Weight-stable Control group
• Overfeeding
30% Overfeeding group

Locations

Country	Name	City	State
United States	Pennington Biomedical Research Center	Baton Rouge	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Pennington Biomedical Research Center	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adipose tissue expansion and remodeling -- in vivo adipocyte formation	Following the consumption of deuterium-labeled water (2H2O; heavy water), adipose tissue biopsies from the subcutaneous abdominal and femoral depots will be collected. The 2H from the heavy water is enriched into the DNA of newly synthesized cells. The primary outcome is to assess changes in new adipocyte formation in vivo and other mechanisms of adipose expansion and remodeling in response to 30% overfeeding (OF group) relative to the weight-stable CTL group.	8 weeks
Secondary	Adipose tissue expansion and remodeling -- in vivo triglyceride synthesis	Following the consumption of deuterium-labeled water (2H2O; heavy water), adipose tissue biopsies from the subcutaneous abdominal and femoral depots will be collected. The 2H from the heavy water is incorporated into the glycerol component of the adipose, providing a measure of new triglyceride synthesis. A secondary outcome is to assess changes in triglyceride synthesis in vivo and other mechanisms of adipose expansion and remodeling in response to 30% overfeeding (OF group) relative to the weight-stable CTL group.	8 weeks
Secondary	Cardiometabolic health outcomes	A secondary outcome is to investigate the correlation between mechanisms of adipose tissue expansion and remodeling with changes in metabolic health outcomes (i.e. abdominal adiposity; insulin sensitivity; ectopic lipid) in response to 30% OF relative to the CTL group.	8 weeks